Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clinial Trials

- PMLiVE

Novartis in-licenses Akcea’s novel cardiovascular therapy

Lp(a) targeting therapy could treat millions

Are you capitalising on your pharma exhibition presence?

When it comes to exhibition success, pharma companies have lots of things to consider. This includes making sure that you have quality pharma exhibition stands that sparks conversations. But, to...

Apex Events and Exhibitions

- PMLiVE

Roche buys gene therapy specialist Spark for $4.3bn

Can compete with rival Novartis in fast-developing area

- PMLiVE

BioMarin prepares for haemophilia A gene therapy data readout, filing

Key long-term data expected in July

- PMLiVE

Innovent gears up for PD-1 inhibitor launch in China

Analysts say the approval marks a move away from developing ‘me-too’ drugs

Biomarin

NICE knocks back BioMarin’s Batten disease drug

£500,000 list price too high without long-term data, says watchdog

- PMLiVE

Amgen, Servier start second phase 3 trial of heart failure hope

Treatment is one of few in underserved area

- PMLiVE

The importance of co-creation with patients

Overcoming the barriers

- PMLiVE

McCann Health’s next challenge: creative differentiation

New global chief creative officer Matt Eastwood talks to PME about McCann Health’s future as a creative advertising agency

- PMLiVE

Merck & Co to buy IO specialists Immune Design for $300m

US giant looks to next generation technology

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links